
The global Heparin market size is predicted to grow from US$ 1923 million in 2025 to US$ 3065 million in 2031; it is expected to grow at a CAGR of 8.1% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the Heparin API.
Global key players of Heparin include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, etc. The top five manufacturers hold a share about 54%. China is dominating the global Heparin market, has a share over 65% in terms of production. Europe and Asia-Pacific are the two largest market, both having a share about 34%, followed by North America, with a share about 30 percent.
The heparin API market is primarily driven by the rising global prevalence of cardiovascular and thromboembolic diseases, along with increasing surgical procedures. Growing aging populations and higher obesity rates contribute to sustained demand for anticoagulants. Additionally, heparin's use in treating COVID-19-associated thrombotic complications has further propelled market expansion. Pharmaceutical industry advancements in emerging markets (e.g., China and India) and the biopharmaceutical sector's demand for high-quality heparin also fuel market growth.
Key trends in the heparin API market include: 1) a technological shift from animal-sourced heparin (porcine intestinal mucosa extraction) to synthetic alternatives (e.g., low-molecular-weight heparin); 2) stringent regulatory requirements for supply chain traceability and quality control; 3) intensified competition from biosimilars, driving process optimization and cost reduction; and 4) the rise of local pharmaceutical players in emerging markets, diversifying the global heparin supply chain.
The “Heparin Industry Forecast” looks at past sales and reviews total world Heparin sales in 2024, providing a comprehensive analysis by region and market sector of projected Heparin sales for 2025 through 2031. With Heparin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Heparin industry.
This Insight Report provides a comprehensive analysis of the global Heparin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Heparin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Heparin market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Heparin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Heparin.
This report presents a comprehensive overview, market shares, and growth opportunities of Heparin market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Heparin Sodium
Heparin Calcium
Segmentation by Application:
UFH
LMWH
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Shenzhen Hepalink Pharmaceutical
Yantai Dongcheng Pharmaceutical
Pfizer
Ǿé
Changzhou Qianhong Biopharma
Nanjing King-friend Biochemical Pharmaceutical
Hebei Changshan Biochemical Pharmaceutical
Qingdao Jiulong Biopharmaceutical
Opocrin
Dongying Tiandong Pharmaceutical
Aspen Oss
Yino Pharma
Nanjing Xinbai Pharmaceutical
Hubei Enoray Biopharmaceutical
Cisen Pharmaceutical
Key Questions Addressed in this Report
What is the 10-year outlook for the global Heparin market?
What factors are driving Heparin market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Heparin market opportunities vary by end market size?
How does Heparin break out by Type, by Application?
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Heparin Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Heparin by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Heparin by Country/Region, 2020, 2024 & 2031
2.2 Heparin Segment by Type
2.2.1 Heparin Sodium
2.2.2 Heparin Calcium
2.3 Heparin Sales by Type
2.3.1 Global Heparin Sales Market Share by Type (2020-2025)
2.3.2 Global Heparin Revenue and Market Share by Type (2020-2025)
2.3.3 Global Heparin Sale Price by Type (2020-2025)
2.4 Heparin Segment by Application
2.4.1 UFH
2.4.2 LMWH
2.5 Heparin Sales by Application
2.5.1 Global Heparin Sale Market Share by Application (2020-2025)
2.5.2 Global Heparin Revenue and Market Share by Application (2020-2025)
2.5.3 Global Heparin Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Heparin Breakdown Data by Company
3.1.1 Global Heparin Annual Sales by Company (2020-2025)
3.1.2 Global Heparin Sales Market Share by Company (2020-2025)
3.2 Global Heparin Annual Revenue by Company (2020-2025)
3.2.1 Global Heparin Revenue by Company (2020-2025)
3.2.2 Global Heparin Revenue Market Share by Company (2020-2025)
3.3 Global Heparin Sale Price by Company
3.4 Key Manufacturers Heparin Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Heparin Product Location Distribution
3.4.2 Players Heparin Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Heparin by Geographic Region
4.1 World Historic Heparin Market Size by Geographic Region (2020-2025)
4.1.1 Global Heparin Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Heparin Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Heparin Market Size by Country/Region (2020-2025)
4.2.1 Global Heparin Annual Sales by Country/Region (2020-2025)
4.2.2 Global Heparin Annual Revenue by Country/Region (2020-2025)
4.3 Americas Heparin Sales Growth
4.4 APAC Heparin Sales Growth
4.5 Europe Heparin Sales Growth
4.6 Middle East & Africa Heparin Sales Growth
5 Americas
5.1 Americas Heparin Sales by Country
5.1.1 Americas Heparin Sales by Country (2020-2025)
5.1.2 Americas Heparin Revenue by Country (2020-2025)
5.2 Americas Heparin Sales by Type (2020-2025)
5.3 Americas Heparin Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Heparin Sales by Region
6.1.1 APAC Heparin Sales by Region (2020-2025)
6.1.2 APAC Heparin Revenue by Region (2020-2025)
6.2 APAC Heparin Sales by Type (2020-2025)
6.3 APAC Heparin Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Heparin by Country
7.1.1 Europe Heparin Sales by Country (2020-2025)
7.1.2 Europe Heparin Revenue by Country (2020-2025)
7.2 Europe Heparin Sales by Type (2020-2025)
7.3 Europe Heparin Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Heparin by Country
8.1.1 Middle East & Africa Heparin Sales by Country (2020-2025)
8.1.2 Middle East & Africa Heparin Revenue by Country (2020-2025)
8.2 Middle East & Africa Heparin Sales by Type (2020-2025)
8.3 Middle East & Africa Heparin Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Heparin
10.3 Manufacturing Process Analysis of Heparin
10.4 Industry Chain Structure of Heparin
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Heparin Distributors
11.3 Heparin Customer
12 World Forecast Review for Heparin by Geographic Region
12.1 Global Heparin Market Size Forecast by Region
12.1.1 Global Heparin Forecast by Region (2026-2031)
12.1.2 Global Heparin Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Heparin Forecast by Type (2026-2031)
12.7 Global Heparin Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Shenzhen Hepalink Pharmaceutical
13.1.1 Shenzhen Hepalink Pharmaceutical Company Information
13.1.2 Shenzhen Hepalink Pharmaceutical Heparin Product Portfolios and Specifications
13.1.3 Shenzhen Hepalink Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Shenzhen Hepalink Pharmaceutical Main Business Overview
13.1.5 Shenzhen Hepalink Pharmaceutical Latest Developments
13.2 Yantai Dongcheng Pharmaceutical
13.2.1 Yantai Dongcheng Pharmaceutical Company Information
13.2.2 Yantai Dongcheng Pharmaceutical Heparin Product Portfolios and Specifications
13.2.3 Yantai Dongcheng Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Yantai Dongcheng Pharmaceutical Main Business Overview
13.2.5 Yantai Dongcheng Pharmaceutical Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer Heparin Product Portfolios and Specifications
13.3.3 Pfizer Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Ǿé
13.4.1 Ǿé Company Information
13.4.2 Ǿé Heparin Product Portfolios and Specifications
13.4.3 Ǿé Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Ǿé Main Business Overview
13.4.5 Ǿé Latest Developments
13.5 Changzhou Qianhong Biopharma
13.5.1 Changzhou Qianhong Biopharma Company Information
13.5.2 Changzhou Qianhong Biopharma Heparin Product Portfolios and Specifications
13.5.3 Changzhou Qianhong Biopharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Changzhou Qianhong Biopharma Main Business Overview
13.5.5 Changzhou Qianhong Biopharma Latest Developments
13.6 Nanjing King-friend Biochemical Pharmaceutical
13.6.1 Nanjing King-friend Biochemical Pharmaceutical Company Information
13.6.2 Nanjing King-friend Biochemical Pharmaceutical Heparin Product Portfolios and Specifications
13.6.3 Nanjing King-friend Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Nanjing King-friend Biochemical Pharmaceutical Main Business Overview
13.6.5 Nanjing King-friend Biochemical Pharmaceutical Latest Developments
13.7 Hebei Changshan Biochemical Pharmaceutical
13.7.1 Hebei Changshan Biochemical Pharmaceutical Company Information
13.7.2 Hebei Changshan Biochemical Pharmaceutical Heparin Product Portfolios and Specifications
13.7.3 Hebei Changshan Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Hebei Changshan Biochemical Pharmaceutical Main Business Overview
13.7.5 Hebei Changshan Biochemical Pharmaceutical Latest Developments
13.8 Qingdao Jiulong Biopharmaceutical
13.8.1 Qingdao Jiulong Biopharmaceutical Company Information
13.8.2 Qingdao Jiulong Biopharmaceutical Heparin Product Portfolios and Specifications
13.8.3 Qingdao Jiulong Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Qingdao Jiulong Biopharmaceutical Main Business Overview
13.8.5 Qingdao Jiulong Biopharmaceutical Latest Developments
13.9 Opocrin
13.9.1 Opocrin Company Information
13.9.2 Opocrin Heparin Product Portfolios and Specifications
13.9.3 Opocrin Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Opocrin Main Business Overview
13.9.5 Opocrin Latest Developments
13.10 Dongying Tiandong Pharmaceutical
13.10.1 Dongying Tiandong Pharmaceutical Company Information
13.10.2 Dongying Tiandong Pharmaceutical Heparin Product Portfolios and Specifications
13.10.3 Dongying Tiandong Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Dongying Tiandong Pharmaceutical Main Business Overview
13.10.5 Dongying Tiandong Pharmaceutical Latest Developments
13.11 Aspen Oss
13.11.1 Aspen Oss Company Information
13.11.2 Aspen Oss Heparin Product Portfolios and Specifications
13.11.3 Aspen Oss Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Aspen Oss Main Business Overview
13.11.5 Aspen Oss Latest Developments
13.12 Yino Pharma
13.12.1 Yino Pharma Company Information
13.12.2 Yino Pharma Heparin Product Portfolios and Specifications
13.12.3 Yino Pharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Yino Pharma Main Business Overview
13.12.5 Yino Pharma Latest Developments
13.13 Nanjing Xinbai Pharmaceutical
13.13.1 Nanjing Xinbai Pharmaceutical Company Information
13.13.2 Nanjing Xinbai Pharmaceutical Heparin Product Portfolios and Specifications
13.13.3 Nanjing Xinbai Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Nanjing Xinbai Pharmaceutical Main Business Overview
13.13.5 Nanjing Xinbai Pharmaceutical Latest Developments
13.14 Hubei Enoray Biopharmaceutical
13.14.1 Hubei Enoray Biopharmaceutical Company Information
13.14.2 Hubei Enoray Biopharmaceutical Heparin Product Portfolios and Specifications
13.14.3 Hubei Enoray Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Hubei Enoray Biopharmaceutical Main Business Overview
13.14.5 Hubei Enoray Biopharmaceutical Latest Developments
13.15 Cisen Pharmaceutical
13.15.1 Cisen Pharmaceutical Company Information
13.15.2 Cisen Pharmaceutical Heparin Product Portfolios and Specifications
13.15.3 Cisen Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Cisen Pharmaceutical Main Business Overview
13.15.5 Cisen Pharmaceutical Latest Developments
14 Research Findings and Conclusion
*If Applicable.
